Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Zleepax Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
Zleepax Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Zleepax: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
ACD-856 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
ACD-856 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
ACD-856: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
Lasmotinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
Lasmotinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Lasmotinib: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
ASN008(Shanghai Auson Pharmaceuticals) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
ASN008(Shanghai Auson Pharmaceuticals) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
ASN008(Shanghai Auson Pharmaceuticals): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position,
Read →
Tezampanel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
Tezampanel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Tezampanel: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
BEPO albumin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
BEPO albumin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
BEPO albumin: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
FHND-91 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
FHND-91 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
FHND-91: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
QLS2401 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
QLS2401 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
QLS2401: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
CJ-30066 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
CJ-30066 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
CJ-30066: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
VAX-A1 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
VAX-A1 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
VAX-A1: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
NK Cell(Y-mAbs Therapeutics) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
NK Cell(Y-mAbs Therapeutics) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
NK Cell(Y-mAbs Therapeutics): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key r
Read →
Ocarocoxib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
Ocarocoxib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Ocarocoxib: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →